Data Sheet (Cat.No.T4475)

TargetMol

JNJ-632

Chemical Properties



CAS No. : 1572510-42-9

Formula: C18H19FN2O4S

Molecular Weight: 378.42

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator.
Targets(IC50)	HBV
In vivo	Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.

Solubility Information

Solubility	DMSO: 125 mg/mL (330.32 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.57 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6426 mL	13.2128 mL	26.4257 mL
5 mM	0.5285 mL	2.6426 mL	5.2851 mL
10 mM	0.2643 mL	1.3213 mL	2.6426 mL
50 mM	0.0529 mL	0.2643 mL	0.5285 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)[J]. Journal of Medicinal Chemistry, 2018.
Yin J, Feng Z, Li Z, et al.Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice.European Journal of Medicinal Chemistry. 2023: 115141.